← All drugs built on NIH-funded research
Fennec Pharmaceuticals · Sodium Thiosulfate
Pedmark: patented from NIH-funded research
Medicare paid, 2024
—
before rebates
Medicare, 2020–2024
$0
Medicaid paid, 2024
—
before rebates
NIH grants behind the patents
$14M
whole-grant totals, not the drug's cost
The public record, link by link
1 · Public money
3 NIH grants to Oregon Health & Science University, $14M in all.2 · Patent
10596190, reported to NIH under R01CA137488, R01NS044687, R37NS044687.3 · FDA approval
Approved Sep 20, 2022, held by Fennec Pharmaceuticals (NDA 212937).4 · Public pays
Not yet in the Medicare or Medicaid spending files, which run to 2024.
The grants
| Grant | Research | Years | NIH paid |
|---|---|---|---|
| R01CA137488 NCI | Two Compartment Models to Improve Brain Tumor Therapy Oregon Health & Science University | 2008–2019 | $7.3M |
| R37NS044687 NINDS | Opening of the Blood Brain Barrier to Antitumor Agents Oregon Health & Science University | 2002–2008 | $3.5M |
| R01NS044687 NINDS | Opening of the blood-brain barrier to antitumor agents Oregon Health & Science University | 2010–2014 | $3.1M |
The patents
- US 10596190FDA-listed expiry Jan 5, 2038
Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
Reported by Oregon Health & Science University
Fennec Pharmaceuticals's side
Drug makers pay for the clinical trials that take a compound from the lab to FDA approval, and they often license the patent from the university and pay royalties on sales. Those terms are not public. The FDA's approval records for Pedmark are linked above, and Fennec Pharmaceuticals's page shows its other drugs on this list. If Fennec Pharmaceuticals wants to add its account, we will publish it here.
How this is built. Universities and companies that use NIH grants must report the inventions those grants produce to NIH, under the Bayh-Dole Act. NIH publishes the patent numbers and the grants they were reported under. We match those patents to the patents drug makers list with the FDA for each approved drug (the Orange Book), then add what Medicare Part D, Part B and Medicaid paid for each drug. Only patents still listed with the FDA appear, so drugs whose patents have expired drop out, and biologics, which the Orange Book does not cover, are not here yet.
What the numbers mean. "NIH grants" is everything NIH paid out on the grants a patent was reported under, from 1985 on. A grant usually paid for more than the one invention, so it is not the cost of the drug. Medicare and Medicaid figures are gross spending before the rebates drug makers pay back, which are confidential. Companies also paid for the clinical trials that took these drugs to approval; each drug page links the company's own filings.
Sources: NIH RePORTER patents reported under NIH grants (from iEdison); NIH RePORTER project funding; FDA Orange Book patent and product files; Medicare Part D Spending by Drug; Medicare Part B Spending by Drug; Medicaid Spending by Drug. Updated 2026-11-05.